Stock comparison
Enovis
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ENOV
Enovis
Market cap
$1.4B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ENOV | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 18F | 67B | IDXX |
| Benjamin Graham | 18F | 72B | IDXX |
| Philip Fisher |
Side-by-side metrics
| Metric | ENOV | IDXX |
|---|---|---|
| Market cap | $1.4B | $42.11B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | - | 31.6x |
| ROIC (TTM) | 1.87% | 40.66% |
| Gross margin | 56.81% | 62.05% |
| Net margin | -49.91% | 24.63% |
| Revenue CAGR 5y | 12.05% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ENOV leads on
- EV/EBIT-vs 31.6x+121%
- P/E (TTM)-vs 39.0x+103%
- Revenue CAGR 5y12.05%vs 7.56%+37%
IDXX leads on
More like IDXX
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.